

Traceable Opioid Material[®] Kits (TOM Kits[®])

The Centers for Disease Control and Prevention (CDC) has developed Traceable Opioid Material[®] Kits (TOM Kits[®]) to support laboratory detection of current and emerging opioids as well as common co-drugs found in fentanyl-containing samples. The CDC has contracted Cayman, an ISO-accredited reference material producer, to manufacture and distribute the Fentanyl Analog Screening (FAS) Kit, FAS Kit – Emergent Panels V1-V4, and FAS Kit – Emergent Drug Panel to qualified labs authorized to handle controlled substances.



TOM Kits[®]

Traceable Opioid Materials, TOM Kits, and the TOM Kits Logo are marks of the US Dept. of Health and Human Services

Overview

The FAS Kit, FAS Kit - Emergent Panels V1-V4, and FAS Kit - Emergent Drug Panel are a collection of reference standards for screening emerging drugs of concern in seized drug or toxicological casework.



CDC
CENTERS FOR DISEASE CONTROL AND PREVENTION™

The mark 'CDC' is owned by the US Dept. of Health and Human Services and is used with permission. Use of this logo is not an endorsement by HHS or CDC of any particular product, service, or enterprise.

Increase Detection Capabilities

Widens the scope of mass spectrometry and immunoassays screening methods

Convenient Format

200 µg of individual standards are packaged in a 96-well Matrix™ tube rack format



Large Coverage

Full set includes reference standards for 250 synthetic opioids and 60 co-drugs

Free of Charge

Available to qualified labs

FAS Kits support government, clinical, and academic research labs performing:

- Seized drug sample testing
- Toxicology testing & other biological sample analysis
- Environmental sample testing
- Drug pharmacology & pharmacokinetics research
- Public health surveillance & drug monitoring
- Analytical method development

The TOM Kits[®] product line, including the FAS Kit, FAS Kit - Emergent Panels V1-V4, and FAS Kit - Emergent Drug Panel, are not for diagnostic use.

APPLY NOW



FAS Kits Available from Cayman

FAS Kit & FAS Kit - Emergent Panels

The FAS Kit and FAS Kit - Emergent Panels V1-V4 contain reference standards that enable labs to screen for 250 synthetic opioid compounds, including more than 210 fentanyl analogs. They are available to qualified labs worldwide.

Provides coverage of 250 synthetic opioid compounds, including:

- Fentanyl analogs
- Nitazenes
- Cinnamylpiperazines
- Utopioids
- Emerging NPS



Kits shown with the FAS Kit- Emergent Drug Panel, below, included.

FAS Kit - Emergent Drug Panel for Detection of Fentanyl Co-Drugs

The FAS Kit - Emergent Drug Panel expands coverage to co-drugs that may be found in fentanyl-containing samples. This panel is distinct from the previous FAS Kit and FAS Kit - Emergent Panels as it does not contain any fentanyl compounds or other synthetic opioids. It is available to qualified labs in the U.S. or its territories.

Provides coverage of 60 fentanyl co-drugs, including:

- Stimulants
- Hallucinogens
- Benzodiazepines
- Synthetic cannabinoids
- Xylazine



Testimonials

“Prior to receiving the [FAS] kits, we were purchasing the neat standards for use across many of our different techniques. The FAS kits have made it very convenient to stay abreast of the emerging fentanyl/opioids without requiring us to spend the costly amount for over 300 compounds”

Ken Hand

Laboratory Director

Cape May County Prosecutor's Office Forensic Laboratory